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DEAR EDITOR, We thank Alunno and colleagues for their
interest in our review [1] and for the data they present
that support a lack of distinction between Sjögren’s syn-
drome (SS) occurring in isolation and SS associated
with the presence of other autoimmune rheumatic dis-
eases. We strongly encourage further comparative re-
search, including at the single cell level, to further
establish the similarities of SS occurring in these differ-
ent settings, or else provide a more concrete rationale
than currently exists for the widely held distinction be-
tween ‘primary’ and ‘secondary’ disease.
We also agree with Alunno et al. that the evaluation of
SS in RA and SLE trials is likely to provide valuable
insights into potential therapies for SS, and we argued in
our review that the absence of such an evaluation has
been a missed opportunity. While we are enthusiastic
about the role of histology as a classifier and outcome
measure in SS [2], we are doubtful that biopsy could be
effectively implemented in a large multicentre trial of a
non-SS autoimmune rheumatic disease. However, evalu-
ation at screening of anti-Ro antibodies alongside tear
and salivary flow assessment in symptomatic patients,
might be feasible. Subsequent objective glandular func-
tion tests and symptomatic assessments could be per-
formed as response measures in the subset with anti-Ro
positive SS. At present there are no approved systemic
immunomodulatory therapies for SS and we should le-
verage opportunities to improve care for this too often
neglected group of patients.
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